Accelerate to discover

Back to filter

Related topics

Introducing Cytek Cloud

Cytek Biosciences

Dec 1, 2022

Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...

See More, Sort More with Cytek Full Spectrum Systems

Cytek Biosciences

Nov 28, 2022

Still wondering whether to join the shift to full spectrum cytometry?  Easily transfer assays from your Cytek Northern...

Demonstrate the value of RareCyte Orion system via web-based Minerva viewer

RareCyte

Nov 25, 2022

The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Dec 8, 2022

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

All inside your incubator: xCELLigence eSight

Agilent technologies

Nov 3, 2022

Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight

Download the newest AVATAR data presented at CAR-TCR

Xcell Biosciences

Oct 21, 2022

Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...

Dec 8, 2022

RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis

RareCyte

Oct 19, 2022

Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...

Show all topics (10)

δT cells and CD8+ T cells targeting of breast cancer cells

Jul 11, 2018

Cancer stem cells (CSCs) are a very rare type of cells which causes metastasis in breast cancer. Their resistance to existing therapies makes effective treatment of breast cancer in later stages very difficult. Here researchers from Cardiff University did a study on their relationship with δT cells and CD8+ T cells to help develop new treatments.
The CSCs are developed with epithelial-to-mesenchymal transition (EMT) and judged based on the CD44 hi/lo phenotype. With these cells, an immunotherapy treatment can be tested with expanded or genetically engineered T cells.

The researchers have found a synergism between γδT cells and CD8+T cells in the eradication of CSCs cells. This suggests that an approach with the combination of MHC-restricted and non-MHC-restricted may be beneficial for breast cancer patients. The paper also offers an interesting and useful tool to study CSC cells.

Scientific paper
Application

Related technologies: Live cell imaging

Brand profile

Etaluma

With a focus on portability, ease of use, high-quality imaging and fast frame-rate, Etaluma developed new concept in simple, affordable, and accessible fluorescence microscopy.

Related products

Latest generation live-cell imaging, 3 colors, 4 positions turret, fully-automated microscope

show detail

Lumascope 620 offers a larger sensor and 3-color fluorescence for the most powerful microscope offered anywhere at this price

show detail

The original single color 488nm excitation fluorescence inverted microscopy

show detail

The true color inverted brightfield microscopy with all of the LumaView software features of the fluorescent LumaScope

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey